Sector News

Novartis taps Amazon know-how for ‘smart’ manufacturing, supply chain

December 5, 2019
Life sciences

Novartis has joined forces with Amazon, drawing on the online retail giant’s technological wizardry to reduce bottlenecks and improve the efficiency of its manufacturing and distribution.

The deal with Amazon Web Services (AWS) is aimed at using the tech company’s cloud-based systems to collect inventory, quality, and production data across its network into central hubs, dubbed Insight Centres, that Novartis says will help it to track production in real time.

The increase in efficacy is essential in light of a shift in the industry towards the production of personalised therapies – such as Novartis’ CAR-T Kymriah (tisagenlecleucel) for blood cancers – which are more complex to make than conventional drugs.

For Novartis, partnering with AWS buys into the many years Amazon has spent developing supply chain and automation systems that enable millions of products to be delivered to hundreds of millions of individuals.

Financial terms of the deal – which comes four years after the two companies first started working together – aren’t being disclosed. The deal also follows Novartis’ wide-ranging partnership with Microsoft to develop artificial intelligence tools for use in its R&D operations.

Novartis’ global head of strategy and operations Amit Nastik said pharma manufacturing as a whole is not as advanced as manufacturing in other industries, and because it is highly regulated “there is a natural hesitancy to try technology that is not fully proven.”

“The Insight Centres will allow us to look at our whole value chain from the start to the end, from how we source our material, how we do our demand forecasting, how we operate at the shop floor, to how we supply our customers and patients,” he added.

For instance, Novartis plans to use AWS Internet of Things (IoT) services to develop better visual inspections of manufacturing sites by generating images that can be analysed using computer vision algorithms.

That will improve its ability to monitor for risks to manufacturing production, such as unplanned downtime or delayed orders.

Meanwhile, for Amazon the deal marks another element of its push into the healthcare sector with deals such as its recent purchase of online symptom checking and triage tool specialist Health Navigator, and online pharmacy player PillPack.

By Phil Taylor

Source: PharmaPhorum

Related News

August 6, 2020

Novartis and a string of high profile backers fund next-gen Treg cell therapy startup GentiBio

Life sciences

OrbiMed, Novartis Venture Fund and RA Capital Management have joined forces to fund and help launch GentiBio. The Boston, Massachusetts-based biotech starts life with a $20 million seed funding with […]

August 6, 2020

Pfizer, Amgen will rake in billions during ‘golden age’ for biosimilars: Analyst

Life sciences

During Pfizer’s second-quarter earnings conference call last week, many analysts were so focused on the company’s potential future payoff from its COVID-19 vaccine effort that they may have overlooked one […]

August 4, 2020

Lilly starts phase 3 test of COVID-19 antibody in nursing homes

Life sciences

Eli Lilly has started a phase 3 trial to evaluate whether its antibody LY-CoV555 stops the residents of nursing homes from developing COVID-19. Lilly has created customized mobile research units to run […]